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A series of 50 gastric endocrine tumors classified according to Rindi et al. [1]
comprised 12 small cell neuroendocrine carcinomas (NEC) and 38 ECL cell
carcinoids, ofwhich 22 associated with typeAchronic atrophic gastritis (A-CAG),
eight with hypertrophic gastropathy due to combined Multiple Endocrine
Neoplasia and Zollinger/Ellison syndrome (MEN/ZES), and eight sporadic.
Variables found to predict tumor malignancy were: size >2 cm, >2 mitoses and
>130 Ki67 positive cells/ 10 high power fields (HPF), grade 2 or 3 histology,
angioinvasion, p53 protein nuclear accumulation, and the presence of a single
tumor. None of these factors increased significantly the predicting ability of
tumor classification itself, although grade 2+3 shows 100 percent negative pre-
dictive value and Ki67 and angioinvasion 100 percent positive predictive value.
When the mostly non-malignant A-CAG and MEN-ZES tumors were analysed
against the mostly malignant sporadic and NEC tumors, a positive predictive
value of90 percent and a negative predictive value of93 percent was obtained.
Investigation of a larger tumor series is under way with the aim to develop an
optimal model for prognostic evaluation ofgastric endocrine tumors.
INTRODUCTION
A few years ago, we developed a clinico-pathologic classification of gastric
endocrine tumors which had pathogenetic, histogenetic as well as prognostic implications
[1, 2]. Two types of gastrin-dependent, well differentiated ECL cell tumors (carcinoids),
arising in a background of type A chronic atrophic gastritis (A-CAG)e or of combined
Multiple Endocrine Neoplasia/Zollinger-Ellison Syndrome (MEN-ZES), respectively, were
separated from a third type ofECL cell tumor, arising independently from known predis-
posing disease (sporadic ECLcell tumor) andfrompoorly differentiated, smallcell "neuro-
endocrine" carcinoma (NEC). Mostgastrin-dependent tumors provedbenign, the sporadic
tumors had a substantial, low grade, malignant potential, while NECs showed high grade
malignancy. The prognostic value ofsuch classification has been confirmed in subsequent
studies of larger tumor series [3-5]. This is an important conclusion considering the fact
that until recently the classic histopathologic criteria for prediction of tumor behavior
have been found of scarce help to separate benign from malignant low-grade endocrine
tumors ofthe gut and pancreas [6].
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Previous analysis of pathologic factors influencing tumor behavior suggested, in
addition to metastases, tumor size, level of gastric wall invasion, mitotic rate, cellular
atypia, and association with carcinoid syndrome [1, 5, 7, 8]. In 1995, all such factors were
considered in a classification of gut, pancreas and lung endocrine tumors proposed by a
group of european pathologists taking part in a meeting on endocrine tumors held in
Monaco [9]. Comparison of the "Monaco" classification with our previous clinicopatho-
logic approach showed broad, though not perfect, overlapping of the two systems when
applied to a large serie of gastric endocrine tumors [4].
In a recent investigation of nonfunctioning pancreatic tumors, 17 clinico-pathologic
and histochemical variables were considered. Eight (size, vascular and perineural invasion,
mitotic and Ki67 proliferative rates, nuclear atypia, capsular penetration and presence of
progesterone receptor) were found to be predictive of tumor behavior at univariate analysis
[10]. Of these factors, at least two, angioinvasion and >2 percent Ki67 proliferative rate,
proved to be strong independent predictors at multivariate analysis. In the present paper
five of the above factors (size, vascular invasion, mitotic and proliferative rates, nuclear
atypia), in addition to the level of gastric wall invasion and local or distant metastases,
have been tested on a series of 50 gastric endocrine tumors, most of which in a previous
study [1] formed the basis for the development of the clinico-pathologic classification.
MATERIAL AND METHODS
Fifty gastric endocrine tumors were selected for study from our pathology files in
Pavia and Varese, including 37 from the series previously published [1]. Tumors were
diagnosed as well differentiated or poorly differentiated based on conventional
histopathologic criteria. Clinicopathologic analysis followed the previously assessed
guidelines [1] and comprised, in addition to atrophic gastritis or MEN-ZES status, age,
sex, presence of local and/or distant metastasis, follow-up and cause of death. Tumor
analysis included: size, site, number of growths, level of infiltration, angioinvasion and
number of mitoses xlO high power field (HPF x 400). The endocrine nature of the 50
tumors was assessed by an extensive reactivity oftumor cells for general endocrine markers
like Grimelius' or Sevier-Munger's silver, chromogranin A, synaptophysin, neuron specific
enolase or protein gene product (PGP) 9.5. In addition, paraffin sections were immunos-
tained for serotonin, gastrin, somatostatin, enteroglucagon, pancreatic polypeptide (PP),
p53 protein and the proliferative marker Ki67 [1, 10, 11, 12].
Statistical investigation of numerical data comprised descriptive statistics (mean ±
standard deviation, frequencies and logistic modelling to measure the association between
each of the considered parameters and the malignancy of the tumor (defined as presence
ofmetastasis and/or deep wall invasion). Logistic odds ratios together with the 95 percent
confidence interval have been computed by the model. Negative and positive predictive
values have been also calculated.
RESULTS
Among the 50 tumors, 12 poorly differentiated, small cell neuroendocrine carcinomas
were separated from 38 well differentiated endocrine tumors. Gastrin (seven positive
cases out of 38 tested), somatostatin (5/35), serotonin (15/34) and PP (5/33) immunore-
activities were restricted to a small minority (<10 percent) of tumor cells. This finding,
coupled with extensive reactivity for markers of neuroendocrine granules or vesicles like
silver stains, chromogranin A and synaptophysin [5, 11] as well as with electron
micoscopy of 18 cases allowed to diagnose all the 38 well differentiated tumors as more
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or less pure ECLcell carcinoids. Focal exocrine differentiation was found in several NECs
and occasional carcinoids.
The main cinicopathologic findings ofthe 50 tumors classified according to Rindi et al.
[1] are reported in Table 1. All but one ofthe 17 metastatic tumors investigated for resulted
to be deeply invasive, with invasion of muscularis propria or beyond. On the other hand
17 out of 18 with deep wall invasion had metastases (Spearman rank test = 0.90,
p = .0000; 95.1 percent concordance in defining malignancy). Thus, deep wall invasion
was assumed as evidence of tumor malignancy in addition to metastases.
InTable 2 the behavior ofthe tumors classified according to Rindi et al. [1] in respect
to five histopathologically assessed variables found to predict behavior in an univariate
logistic regression model (Table 3) is given. It appears that, by assuming type 1 and 2
tumors as non-malignant and type 3 and 4 tumors as malignant, Rindi's classification cor-
rectly predicts tumors in 93 percent of cases and as malignant in 90 percent of cases. In
an attempt to increase the predictive power ofthe classification, the histopathologic para-
meters ofTables 2 and 3 were added separately in a model using classification type only
as dependent variable. In no case the predictive ability of the multivariate models
increased compared to that oftumor type alone. However, Ki67 proliferative index signifi-
cantly increased the amount ofexplained variation (log likelihood ratio test: p = 0.03). In
addition, all the 12 cases showing blood vessels invasion in the primary tumor were found
to be metastatic. Interestingly, nuclear p53 protein accumulation was detected in eight out
of 12 NECs, two out of six sporadic (one of which metastatic) and none of 18 CAG or
MEN/ZES associated carcinoids.
DISCUSSION
From the above and previous findings it seems clear that the classification of gastric
endocrine tumors based on simple clinico-pathologic criteria developed by Rindi et al. [1]
remains the easiest and more informative approach to the study of such tumors. As a
strong correlation was found between deep wall invasion (which can be assessed in vivo
by endoscopic ultrasonography) and metastases, tumors invading the muscularis propria
or beyond were included among malignant cases.
Inprinciple, addition ofsize, mitotic rate, Ki67 proliferative marker, histologic grade,
p53 protein accumulation, and angioinvasion should be ofhelp in predicting metastases and
more or less malignant behavior. From our findings, it seems that the first four criteria,
which can be easily assessed by combined endoscopic and histologic examination, are
likely to provide useful information for the identification of tumors requiring surgery,
including the rare malignant cases among gastrin-dependent A-CAG or MEN-ZES asso-
ciated tumors and the higher risk cases among sporadic tumors. Both 53 protein and angio-
invasion were mostly confined to small cell neuroendocrine carcinomas, an expected finding
in the case of p53, but not of angioinvasion. In the case of well differentiated gastric
endocrine tumors angioinvasion seems less informative than it could be anticipated from
previous findings on pancreatic tumors [10]. On the other hand a size above 2 cm seems
morepredictiveofmalignancyinthecaseofgastricthanofpancreaticendocrinetumors, while
a Ki67proliferative index ofmore than threepercentorwithmore than 150positive cells per
1OHPF seems to be equally indicative ofmalignancy forbothpancreatic and gastric tumors.
As already suggested for pancreatic tumors [10], an optimal model for prognostic
evaluation of gastric endocrine tumors should allow to identify four tumor categories: 1)
benign or low risk, 2) increased risk, 3) malignant low grade and 4) malignant high grade.
To reach this goal, investigation of a larger tumor series allowing careful multivariate
analysis of independent predictive factors is warranted.
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